Company: CERO
Filing Date: 2025-04-25
Form Type: PRE 14A
Source: 0001213900-25-035562
Chunk: 39

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-25
Form: PRE 14A
Chunk 39
---
 or (ii) the effectiveness of a registration statement for resale of such shares under the Securities Act. The issuance of Common Stock upon the conversion of the Series D Preferred Stock at such a reduced conversion or exercise price may result in certain investors in the April 2025 Private Placement (the “April 2025 Investors”) acquiring more than 20% of the amount of Common Stock issued and outstanding prior to the April 2025 Private Placement at a price below the Minimum Price. Accordingly, the Company needs stockholder approval of the issuance of shares of Common Stock upon any such reset of the conversion of the Series D Preferred Stock. On the Record Date, assuming the issuance of all shares of Common Stock upon conversion of all of the shares of the Series D Preferred Stock (including the 6,250shares of Series D Preferred Stock issued and outstanding and the 3,750shares of Series D Preferred Stock that may be issued in additional closings), the April 2025 Investors would own approximately 12,820,513 million shares of Common Stock, assuming conversion at the initial conversion price of $0.78 per share. Such shares would constitute approximately 71.3% of the then -outstandingCommon Stock after the issuance of such shares. Because the conversion price of the Series D Preferred Stock may be adjusted, the number of shares that will actually be issued may be more or less than such number of shares. In addition, under the terms of the Series D Preferred Stock, an April 2025 Investor may not convert the Series D Preferred Stock to the extent (but only to the extent) such April 2025 Investor or any of its affiliates would beneficially own a number of shares of Common Stock which would exceed 4.99%, or, at the election of the April 2025 Investor, a number of shares of Common Stock which would exceed 9.99%. April 2025 Private Placement In April 2025, the Company consummated the April 2025 Private Placement of 6,250shares of Series D Preferred Stock pursuant to the April 2025 Securities Purchase Agreement, dated April 21, 2025 (the “April 2025 Securities Purchase Agreement”), for aggregate proceeds of approximately $5 million, paid in cash or through the transfer of certain Transfer Shares (as defined in the April 2025 Securities Purchase Agreement) in lieu of cash, and agreed to issue up to 3,750 additional shares of Series D Preferred Stock for cash proceeds of up to $3million at one or